Avalo CMO Executes Option Exercise and Share Sale; Analysts Maintain Bullish Stance Ahead of Phase II Readouts
Avalo Therapeutics' Chief Medical Officer, Doyle Mittie, completed a matched exercise-and-sale transaction on April 1, 2026, selling 679 shares of common stock at $16.00 and exercising options to buy 679 shares at $8.04. The moves were conducted under a pre-arranged Rule 10b5-1 plan adopted November 13, 2025. Meanwhile, several analysts reiterated …